Mitochondrial genotype and breast cancer predisposition

Oncology Reports

Volumn 24, Issue 6, 2010, Pages 1521-1534

  Czarnecka, Anna M ^a,b   Krawczyk, Tomasz ^c   Plak, Katarzyna ^a   Klemba, Aleksandra ^a   Zdrozny, Marek ^c   Arnold, Rebecca S ^h   Kofler, Barbara ^g   Golik, Pawel ^a,d   Szybinska, Aleksandra ^e   Lubinski, Jan ^f   Mossakowska, Malgorzata ^e   Bartnik, Ewa ^a,d   Petros, John A ^h,i  

^a UNIVERSITY OF WARSAW   (Poland)

^b Laboratory of Molecular Diagnostics   (Poland)

^c POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^d INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^e INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^f POMERANIAN MEDICAL UNIVERSITY   (Poland)

^g PARACELSUS MEDICAL UNIVERSITY   (Austria)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Mitochondrial genotype

Indexed keywords

MITOCHONDRIAL DNA;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; MITOCHONDRION; POLAND; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 78649429468     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00001014     Document Type: Article

References (104)

1. Olopade OI, Grushko TA, Nanda R and Huo D: Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14: 7988-7999, 2008.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Levi F, Lucchini F, Negri E and La Vecchia C: Continuing declines in cancer mortality in the European Union. Ann Oncol 18: 593-595, 2007.
5. Balleine RL, Webster LR, Davis S, et al: Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 14: 8244-8252, 2008.
6. Geyer FC, Marchio C and Reis-Filho JS: The role of molecular analysis in breast cancer. Pathology 41: 77-88, 2009.
7. Welcsh PL and King MC: BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 10: 705-713, 2001.
8. Foulkes WD and Narod SA: Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Clin Invest Med 18: 473-483, 1995.
9. Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L and Freedman AN: Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 42: 749-755, 2005.
10. Lubinski J, Korzen M, Gorski B, et al: Breast cancer susceptibility genes. J BUON 12 (Suppl 1.): S23-S29, 2007.
11. Jakubowska A, Jaworska K, Cybulski C, et al: Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer 45: 837-842, 2009.
12. Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457-1466, 2008.
13. Walsh T, Casadei S, Coats KH, et al: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379-1388, 2006.
14. Debniak T, Scott RJ, Huzarski T, et al: XPD common variants and their association with melanoma and breast cancer risk. Breast Cancer Res Treat 98: 209-215, 2006. (Pubitemid 44050771)
15. Simpson S: PALB2-new breast-cancer susceptibility gene. Lancet Oncol 8: 105, 2007.
16. Garcia-Closas M and Chanock S: Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 14: 8000-8009, 2008.
17. Lubinski J, Korzen M, Gorski B, et al: Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Res Treat 114: 121-126, 2009.
18. Pietka G, Kukwa W, Bartnik E, Scinska A and Czarnecka AM: [Mitochondrial DNA mutations in the pathogenesis in the head and neck squamous cell carcinoma]. Otolaryngol Pol 62: 158-164, 2008.
19. Plak K, Kukwa W, Bartnik E, et al: [The impact of mtDNA mutations on proteins structure in selected types of cancer]. Postepy Biochem 54: 151-160, 2008.
20. Brandon M, Baldi P and Wallace DC: Mitochondrial mutations in cancer. Oncogene 25: 4647-4662, 2006.
21. Czarnecka A, Golik P and Bartnik E: Mitochondrial DNA mutations in human neoplasia. J Appl Genet 47: 67-78, 2006.
22. Wallace DC: A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39: 359-407, 2005.
23. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL and Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis 26: 145-152, 2005.
24. Tseng LM, Yin PH, Chi CW, et al: Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer 45: 629-638, 2006.
25. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ and Fletcher SW: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338: 1089-1096, 1998.
26. NIH: National Institutes of Health Consensus Development Conference Statement: breast cancer screening for women ages 40-49, January 21-23, 1997. National Institutes of Health Consensus Developmental Panel. J Natl Cancer Inst Monogr: vii-xviii, 1997.
27. Berg WA, Blume JD, Cormack JB, et al: Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299: 2151-2163, 2008.
28. Tyrer J, Duffy SW and Cuzick J: A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23: 1111-1130, 2004.
29. Lawson HW, Henson R, Bobo JK and Kaeser MK: Implementing recommendations for the early detection of breast and cervical cancer among low-income women. Oncology (Williston Park) 14: 1528-1530, 1638, 1641-1522 passim, 2000.
30. Czarnecka AM, Marino Gammazza A, Di Felice V, Zummo G and Cappello F: Cancer as a 'Mitochondriopathy'. J Cancer Mol 3: 71-79, 2007.
31. Petros JA, Baumann AK, Ruiz-Pesini E, et al: mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102: 719-724, 2005.
32. Ishikawa K, Takenaga K, Akimoto M, et al: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320: 661-664, 2008.
33. Czarnecka AM and Bartnik E: Mitochondrial DNA mutations in tumors. In: Cellular Respiration and Carcinogenesis. Apte SP and Sarangarajan R (eds). Humana Press, New York, pp1-12, 2009.
34. Czarnecka AM, Krawczyk T, Czarnecki JS, et al: Methodology for mitochondrial DNA research in oncology: goals and pitfalls. ARS Medica Tomitana XIV: pp48-64, 2008.
35. Czarnecka AM, Krawczyk T, Zdrozny M, et al: Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast Cancer Res Treat: 511-518, 2010.
36. Klemba A, Kukwa W, Bartnik E, et al: [Molecular biology of endometrial carcinoma]. Postepy Hig Med Dosw (Online) 62: 420-432, 2008.
37. Plak K, Czarnecka AM, Krawczyk T, Golik P and Bartnik E: Breast cancer as a mitochondrial disorder (Review). Oncol Rep 21: 845-851, 2009.
38. Aikhionbare FO, Khan M, Carey D, Okoli J and Go R: Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression? Mol Cancer 3: 30, 2004.
39. Datta S, Majumder M, Biswas NK, Sikdar N and Roy B: Increased risk of oral cancer in relation to common Indian mitochondrial polymorphisms and autosomal GSTP1 locus. Cancer 110: 1991-1999, 2007.
40. Singh KK and Kulawiec M: Mitochondrial DNA polymorphism and risk of cancer. Methods Mol Biol 471: 291-303, 2009.
41. Ha PK, Tong BC, Westra WH, et al: Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res 8: 2260-2265, 2002.
42. Fliss MS, Usadel H, Caballero OL, et al: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287: 2017-2019, 2000.
43. Piechota J, Tonska K, Nowak M, Kabzinska D, Lorenc A and Bartnik E: Comparison between the Polish population and European populations on the basis of mitochondrial morphs and haplogroups. Acta Biochim Pol 51: 883-895, 2004.
44. Ingman M and Gyllensten U: mtDB: Human Mitochondrial Genome Database, a resource for population genetics and medical sciences. Nucleic Acids Res 34: D749-D751, 2006.
45. Ruiz-Pesini E, Lott MT, Procaccio V, et al: An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res 35: D823-D828, 2007.
46. Tavassoli FA and Devilee P: World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs. IARC Press-WHO, 2003.
47. Mossakowska M, Barcikowska M, Broczek K, et al: Polish Centenarians Programme. Multidisciplinary studies of successful ageing: aims, methods, and preliminary results. Exp Gerontol 43: 238-244, 2008.
48. Jakubowska A, Gronwald J, Menkiszak J, et al: Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3′ untranslated region polymorphism. BMC Cancer 8: 90, 2008.
49. Booker LM, Habermacher GM, Jessie BC, et al: North American white mitochondrial haplogroups in prostate and renal cancer. J Urol 175: 468-472, 2006.
50. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM and Howell N: Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet 23: 147, 1999.
51. Wiesbauer M, Meierhofer D, Mayr JA, Sperl W, Paulweber B and Kofler B: Multiplex primer extension analysis for rapid detection of major European mitochondrial haplogroups. Electrophoresis 27: 3864-3868, 2006.
52. Finnila S, Lehtonen MS and Majamaa K: Phylogenetic network for European mtDNA. Am J Hum Genet 68: 1475-1484, 2001.
53. Macaulay V, Richards M, Hickey E, et al: The emerging tree of West Eurasian mtDNAs: a synthesis of control-region sequences and RFLPs. Am J Hum Genet 64: 232-249, 1999.
54. Torroni A, Huoponen K, Francalacci P, et al: Classification of European mtDNAs from an analysis of three European populations. Genetics 144: 1835-1850, 1996.
55. Thompson JD, Higgins DG and Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680, 1994.
56. Anderson S, Bankier AT, Barrell BG, et al: Sequence and organization of the human mitochondrial genome. Nature 290: 457-465, 1981.
57. Sheskin DJ: Handbook of parametric and non-parametric statistical procedures. Chapman & Hall, Boca Raton, FL, 2007.
58. Campbell I: Chi-squared and Fisher-Irwin tests of two-bytwo tables with small sample recommendations. Stat Med 26: 3661-3675, 2007.
59. Fleiss JL, Levin B, Cho Paik M and Fleiss J: Statistical methods for rates and proportions. Wiley-Interscience Inc., San Francisco, CA, 2003.
60. Rosner B: Fundamentals of Biostatistics. Duxbury Press, Florence, KY 2005.
61. Malyarchuk BA, Grzybowski T, Derenko MV, Czarny J, Wozniak M and Miscicka-Sliwka D: Mitochondrial DNA variability in Poles and Russians. Ann Hum Genet 66: 261-283, 2002.
62. Covarrubias D, Bai RK, Wong LJ and Leal SM: Mitochondrial DNA variant interactions modify breast cancer risk. J Hum Genet 53: 924-928, 2008.
63. Borella L: [The European countries confronting cancer: a set of indicators assessing public health status]. Bull Cancer 95: 1053-1062, 2008.
64. Losanoff JE, Zhu W, Qin W, Mannello F and Sauter ER: Can mitochondrial DNA mutations in circulating white blood cells and serum be used to detect breast cancer? Breast 17: 540-542, 2008.
65. Jakupciak JP, Maggrah A, Maragh S, et al: Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0. BMC Cancer 8: 95, 2008.
66. Isaacs C, Cavalli LR, Cohen Y, et al: Detection of LOH and mitochondrial DNA alterations in ductal lavage and nipple aspirate fluids from high-risk patients. Breast Cancer Res Treat 84: 99-105, 2004.
67. Tan DJ, Bai RK and Wong LJ: Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res 62: 972-976, 2002.
68. Tseng LM, Yin PH, Tsai YF, et al: Association between mitochondrial DNA 4,977 bp deletion and NAD(P)H:quinone oxidoreductase 1 C609T polymorphism in human breast tissues. Oncol Rep 21: 1169-1174, 2009.
69. Gochhait S, Bhatt A, Sharma S, Singh YP, Gupta P and Bamezai RN: Concomitant presence of mutations in mitochondrial genome and p53 in cancer development, a study in north Indian sporadic breast and esophageal cancer patients. Int J Cancer 123: 2580-2586, 2008.
70. Bhat A, Koul A, Sharma S, et al: The possible role of 10398A and 16189C mtDNA variants in providing susceptibility to T2DM in two North Indian populations: a replicative study. Hum Genet 120: 821-826, 2007.
71. Canter JA, Kallianpur AR, Parl FF and Millikan RC: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 65: 8028-8033, 2005.
72. Mims MP, Hayes TG, Zheng S, et al: Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res 66: 1880; author reply 1880-1881, 2006.
73. Wang Y, Liu VW, Tsang PC, et al: Microsatellite instability in mitochondrial genome of common female cancers. Int J Gynecol Cancer 16 (Suppl. 1): 259-266, 2006.
74. Zhou S, Kachhap S, Sun W, et al: Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci USA 104: 7540-7545, 2007.
75. Pezzotti A, Kraft P, Hankinson SE, Hunter DJ, Buring J and Cox DG: The mitochondrial A10398G polymorphism, interaction with alcohol consumption, and breast cancer risk. PLoS ONE 4: e5356, 2009.
76. Bai RK, Leal SM, Covarrubias D, Liu A and Wong LJ: Mitochondrial genetic background modifies breast cancer risk. Cancer Res 67: 4687-4694, 2007.
77. Parrella P, Xiao Y, Fliss M, et al: Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res 61: 7623-7626, 2001.
78. Salas A, Carracedo A, Macaulay V, Richards M and Bandelt HJ: A practical guide to mitochondrial DNA error prevention in clinical, forensic, and population genetics. Biochem Biophys Res Commun 335: 891-899, 2005.
79. Wang CY, Wang HW, Yao YG, Kong QP and Zhang YP: Somatic mutations of mitochondrial genome in early stage breast cancer. Int J Cancer 121: 1253-1256, 2007.
80. Salas A, Yao YG, Macaulay V, Vega A, Carracedo A and Bandelt HJ: A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2: e296, 2005.
81. Parson W and Bandelt HJ: Extended guidelines for mtDNA typing of population data in forensic science. Forensic Sci Int Genet 1: 13-19, 2007. (Pubitemid 46696597)
82. Bandelt HJ and Salas A: Contamination and sample mix-up can best explain some patterns of mtDNA instabilities in buccal cells and oral squamous cell carcinoma. BMC Cancer 9: 113, 2009.
83. Bandelt HJ, Yao YG, Salas A, Kivisild T and Bravi CM: High penetrance of sequencing errors and interpretative short-comings in mtDNA sequence analysis of LHON patients. Biochem Biophys Res Commun 352: 283-291, 2007.
84. Bandelt HJ, Quintana-Murci L, Salas A and Macaulay V: The fingerprint of phantom mutations in mitochondrial DNA data. Am J Hum Genet 71: 1150-1160, 2002.
85. Gomez-Zaera M, Abril J, Gonzalez L, et al: Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients. Mutat Res 595: 42-51, 2006.
86. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J and Sobrinho-Simoes M: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 160: 1857-1865, 2002.
87. Bandelt HJ, Yao YG, Bravi CM, Salas A and Kivisild T: Median network analysis of defectively sequenced entire mitochondrial genomes from early and contemporary disease studies. J Hum Genet 54: 174-181, 2009.
88. Tzen CY, Mau BL and Wu TY: ND4 mutation in transitional cell carcinoma: does mitochondrial mutation occur before tumorigenesis? Mitochondrion 7: 273-278, 2007.
89. Jassem J, Jassem E, Jakobkiewicz-Banecka J, et al: P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with non-small cell lung carcinoma. Cancer 100: 1951-1960, 2004.
90. Bandelt HJ, Salas A and Bravi CM: What is a 'novel' mtDNA mutation, and does 'novelty' really matter? J Hum Genet 51: 1073-1082, 2006.
91. Raule N, Sevini F, Santoro A, Altilia S and Franceschi C: Association studies on human mitochondrial DNA: methodological aspects and results in the most common age-related diseases. Mitochondrion 7: 29-38, 2007.
92. Yang J, Zhu Y, Tong Y, et al: The novel G10680A mutation is associated with complete penetrance of the LHON/T14484C family. Mitochondrion 9: 273-278, 2009.
93. Ji Y, Zhang AM, Jia X, et al: Mitochondrial DNA haplogroups M7b1′2 and M8a affect clinical expression of leber hereditary optic neuropathy in Chinese families with the m.11778G→a mutation. Am J Hum Genet 83: 760-768, 2008.
94. Darvishi K, Sharma S, Bhat AK, Rai E and Bamezai RN: Mitochondrial DNA G10398A polymorphism imparts maternal Haplogroup N a risk for breast and esophageal cancer. Cancer Lett 249: 249-255, 2007.
95. Hendrickson SL, Hutcheson HB, Ruiz-Pesini E, et al: Mitochondrial DNA haplogroups influence AIDS progression. AIDS 22: 2429-2439, 2008.
96. Baudouin SV, Saunders D, Tiangyou W, et al: Mitochondrial DNA and survival after sepsis: a prospective study. Lancet 366: 2118-2121, 2005.
97. Hibi K, Nakayama H, Yamazaki T, et al: Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer 94: 429-431, 2001.
98. Ye C, Gao YT, Wen W, et al: Association of mitochondrial DNA displacement loop (CA)n dinucleotide repeat polymorphism with breast cancer risk and survival among Chinese women. Cancer Epidemiol Biomarkers Prev 17: 2117-2122, 2008.
99. Ruppert V, Nolte D, Aschenbrenner T, Pankuweit S, Funck R and Maisch B: Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome. Biochem Biophys Res Commun 318: 535-543, 2004.
100. Liou CW, Lin TK, Huang FM, et al: Association of the mitochondrial DNA 16189 T to C variant with lacunar cerebral infarction: evidence from a hospital-based case-control study. Ann N Y Acad Sci 1011: 317-324, 2004.
101. Wallace DC: Mitochondrial diseases in man and mouse. Science 283: 1482-1488, 1999.
102. Wallace DC: Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 70: 363-374, 2005.
103. Munakata K, Tanaka M, Mori K, et al: Mitochondrial DNA 3644T→C mutation associated with bipolar disorder. Genomics 84: 1041-1050, 2004.
104. Elliott HR, Samuels DC, Eden JA, Relton CL and Chinnery PF: Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 83: 254-260, 2008.